Promising Results: Pembrolizumab Enhances Mesothelioma Treatment
|

Promising Results: Pembrolizumab Enhances Mesothelioma Treatment

Pleural mesothelioma is a challenging cancer caused by asbestos exposure. It is often diagnosed in advanced stages with limited treatment options. However, a glimmer of hope has emerged in recent years with a groundbreaking approach. The addition of pembrolizumab to standard chemotherapy has shown promising results in improving the overall survival of patients with this devastating disease. A Global Effort A phase 3 clinical trial was conducted across 51 hospitals in Canada, Italy, and France. Eligible participants, aged 18 years or older, had previously untreated advanced pleural mesothelioma and a good performance status. They were randomly divided into two groups. One received intravenous chemotherapy with or without pembrolizumab. A Game-Changing Outcome The trial ran from January 2017 to September 2020…